admin

AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in ETESIAN Phase IIb trial – AstraZeneca

Previous article

Dr. Vanessa Northington Gamble Discusses Intersection of Race and Infectious Disease for 2022 Sonenshine Endowed Lecture Series – Old Dominion University

Next article

You may also like

Comments

發表迴響

More in 今日NEWS